Fostamatinib is proposed for all three MCL stage transitions (Figure 4 and Figure 5) via protein targets, such as SYK, BTK, MAP2K2 or PTK2B, that are affected indirectly. Here, MAP2K2 is linked to mantle cell lymphoma.